Aberrant SLC6A14 Expression Promotes Proliferation and Metastasis of Colorectal Cancer Via Enhancing the JAK2/STAT3 Pathway

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Jan 20

PMID 33469314

Citations 10

Authors

Hongli Mao

Jinxiu Sheng

Jinlin Jia

Chang Wang

Shanfeng Zhang

Hongle Li

Fucheng He

Affiliations

Soon will be listed here.

Abstract

Background: Solute carrier family 6 member 14 (SLC6A14) is a high-capacity amino acid transporter in mammalian cells. It has gained increasing attention for its potential involvement in the progression and metabolic reprogramming of various malignant tumors. However, the role of SLC6A14 in colorectal cancer (CRC) remains unclear.

Methods: Real-time polymerase chain reaction (qRT-PCR), immunoblotting and immunohistochemistry were carried out to detect the expression level of SLC6A14 in human CRC tissues and CRC-derived cell lines. HCT-116 and Caco-2 cell lines were selected to conduct in vitro functional studies. Cell Counting Kit-8 (CCK-8), colony formation, flow cytometry, cell migration and invasion assays were performed to investigate the role of SLC6A14 in CRC cells. Besides, azoxymethane/dextran sulfate sodium salt (AOM/DSS)-induced CRC and tumor xenograft models were constructed to explore the effects of SLC6A14 blockade or overexpression during tumor progression in vivo.

Results: SLC6A14 was substantially increased in human CRC samples and higher levels of SLC6A14 was correlated with advanced tumor stage, lymph node metastasis and dismal survival of CRC patients. SLC6A14 markedly promoted cell growth, inhibited cell apoptosis, and exacerbated migration and invasion of CRC cells in vitro. Mechanistically, SLC6A14 aggravated these malignant phenotypes through activating JAK2/STAT3 signaling pathway, and inhibiting JAK2/STAT3 signaling with specific inhibitors could reverse SLC6A14-mediated tumorigenic effects. Besides, two different animal studies verified the tumor-promoting effect of SLC6A14 in CRC.

Conclusion: Our data illustrated the crucial function of SLC6A14 during CRC progression, suggesting SLC6A14/JAK2/STAT3 axis may serve as novel therapeutic targets for patients with CRC.

Citing Articles

Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.

Tambay V, Raymond V, Voisin L, Meloche S, Bilodeau M Int J Mol Sci. 2024; 25(14).

PMID: 39062801 PMC: 11277143. DOI: 10.3390/ijms25147558.

Machine learning identifies SLC6A14 as a novel biomarker promoting the proliferation and metastasis of pancreatic cancer via Wnt/β-catenin signaling.

Dang C, Bian Q, Wang F, Wang H, Liang Z Sci Rep. 2024; 14(1):2116.

PMID: 38267509 PMC: 10808089. DOI: 10.1038/s41598-024-52646-8.

Phenotypic profiling of solute carriers characterizes serine transport in cancer.

Papalazarou V, Newman A, Huerta-Uribe A, Legrave N, Falcone M, Zhang T Nat Metab. 2023; 5(12):2148-2168.

PMID: 38066114 PMC: 10730406. DOI: 10.1038/s42255-023-00936-2.

Membrane transporters in cell physiology, cancer metabolism and drug response.

Alam S, Doherty E, Ortega-Prieto P, Arizanova J, Fets L Dis Model Mech. 2023; 16(11).

PMID: 38037877 PMC: 10695176. DOI: 10.1242/dmm.050404.

analysis of the solute carrier (SLC) family in cancer indicates a link among DNA methylation, metabolic adaptation, drug response, and immune reactivity.

Lavoro A, Falzone L, Tomasello B, Conti G, Libra M, Candido S Front Pharmacol. 2023; 14:1191262.

PMID: 37397501 PMC: 10308049. DOI: 10.3389/fphar.2023.1191262.

References

Cormerais Y, Massard P, Vucetic M, Giuliano S, Tambutte E, Durivault J . The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5). J Biol Chem. 2018; 293(8):2877-2887. PMC: 5827425. DOI: 10.1074/jbc.RA117.001342. View

Coothankandaswamy V, Cao S, Xu Y, Prasad P, Singh P, Reynolds C . Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol. 2016; 173(23):3292-3306. PMC: 5738662. DOI: 10.1111/bph.13616. View

Zhang Y, Zhang Y, Sun K, Meng Z, Chen L . The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol. 2018; 11(1):1-13. PMC: 6359923. DOI: 10.1093/jmcb/mjy052. View

CHRISTENSEN H . Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990; 70(1):43-77. DOI: 10.1152/physrev.1990.70.1.43. View

Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M . Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017; 18(1). PMC: 5297828. DOI: 10.3390/ijms18010197. View

Sikder M, Sivaprakasam S, Brown T, Thangaraju M, Bhutia Y, Ganapathy V . SLC6A14, a Na+/Cl--coupled amino acid transporter, functions as a tumor promoter in colon and is a target for Wnt signaling. Biochem J. 2020; 477(8):1409-1425. PMC: 7182441. DOI: 10.1042/BCJ20200099. View

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S . Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005; 11(12):1314-21. DOI: 10.1038/nm1325. View

Lang X, Green M, Wang W, Yu J, Choi J, Jiang L . Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discov. 2019; 9(12):1673-1685. PMC: 6891128. DOI: 10.1158/2159-8290.CD-19-0338. View

Sun K, Zhao X, Wan J, Yang L, Chu J, Dong S . The diagnostic value of long non-coding RNA MIR31HG and its role in esophageal squamous cell carcinoma. Life Sci. 2018; 202:124-130. DOI: 10.1016/j.lfs.2018.03.050. View

10.

Penheiter A, Erdogan S, Murphy S, Hart S, Lima J, Rohakhtar F . Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma. Biomed Res Int. 2015; 2015:593572. PMC: 4461733. DOI: 10.1155/2015/593572. View

11.

Wang Z, Yin M, Wang R, Liu X, Yan D . Bit1 Silencing Enhances the Proliferation, Migration, and Invasion of Glioma Cells Through Activation of the IL-6/STAT3 Pathway. Onco Targets Ther. 2020; 13:2469-2481. PMC: 7102891. DOI: 10.2147/OTT.S240081. View

12.

Salisbury T, Arthur S . The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer. Int J Mol Sci. 2018; 19(8). PMC: 6121554. DOI: 10.3390/ijms19082373. View

13.

White M, Frigo D . Regulation of SLC1A4 and SLC1A5 in Prostate Cancer-Response. Mol Cancer Res. 2018; 16(11):1811-1812. DOI: 10.1158/1541-7786.MCR-18-0240. View

14.

van Geldermalsen M, Wang Q, Nagarajah R, Marshall A, Thoeng A, Gao D . ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2015; 35(24):3201-8. PMC: 4914826. DOI: 10.1038/onc.2015.381. View

15.

Koppula P, Zhang Y, Shi J, Li W, Gan B . The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017; 292(34):14240-14249. PMC: 5572906. DOI: 10.1074/jbc.M117.798405. View

16.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

17.

Bollrath J, Phesse T, von Burstin V, Putoczki T, Bennecke M, Bateman T . gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15(2):91-102. DOI: 10.1016/j.ccr.2009.01.002. View

18.

Gupta N, Miyauchi S, Martindale R, Herdman A, Podolsky R, Miyake K . Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta. 2005; 1741(1-2):215-23. DOI: 10.1016/j.bbadis.2005.04.002. View

19.

Babu E, Bhutia Y, Ramachandran S, Gnanaprakasam J, Prasad P, Thangaraju M . Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer. Biochem J. 2015; 469(1):17-23. DOI: 10.1042/BJ20150437. View

20.

Chu J, Li H, Xing Y, Jia J, Sheng J, Yang L . LncRNA MNX1-AS1 promotes progression of esophageal squamous cell carcinoma by regulating miR-34a/SIRT1 axis. Biomed Pharmacother. 2019; 116:109029. DOI: 10.1016/j.biopha.2019.109029. View